Clinical trials with 1-acetyl-2-picolinoylhydrazine (NSC-68626) in children

Area of Science:

• Pediatric Oncology
• Pharmacology
• Cancer Research

Background:

• Malignant neoplasms pose a significant health challenge in pediatric populations.
• Novel therapeutic agents are continuously sought to improve treatment outcomes for childhood cancers.

Purpose of the Study:

• To evaluate the efficacy and safety of 1-acetyl-2-picolinoylhydrazine in treating pediatric malignant neoplasms.
• To document complete regressions and identify potential adverse effects of the drug.

Main Methods:

• A cohort of thirty-seven children diagnosed with various malignant neoplasms received treatment with 1-acetyl-2-picolinoylhydrazine.
• Treatment outcomes, including tumor response and adverse events, were systematically monitored.

Main Results:

• Complete regressions were observed in three patients: one with embryonal rhabdomyosarcoma, one with generalized histiocytosis-X, and one with Hodgkin's disease.
• One patient experienced renal failure, though a direct causal link to the drug was not established.
• Adverse effects were generally mild, predominantly nausea and vomiting.

Conclusions:

• 1-acetyl-2-picolinoylhydrazine demonstrated potential in inducing complete regressions in specific pediatric malignancies.
• The drug appears to have a manageable safety profile, with mild gastrointestinal side effects being the most common.
• Further investigation may be warranted to explore the therapeutic role of this agent in pediatric oncology.